TransCode Therapeutics is a clinical-stage company developing TTX-MC138, an RNA drug that blocks microRNA-10b, for cancers including colorectal cancer that remains detectable after surgery; it is not approved.
TransCode's case rests on TTX-MC138: 10 of 14 evaluable Phase 1a patients achieved stable disease, with no dose-limiting toxicities. Its colorectal Phase 2a targets ctDNA-positive patients after curative-intent treatment. Management's runway guidance, including July financing, extends to approximately year-end 2026, with substantial going-concern doubt. A formal strategic process adds potential licensing, asset-sale and partnership routes to support development, but no transaction is assured. Yorkville notes remain approximately $4.1 million outstanding after prepayment. Seviprotimut-L development depends on available funding.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: TransCode raises enough to keep going
Will new financing or a strategic transaction provide enough resources to continue clinical development beyond the guided runway?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
TransCode explores strategic deals as funding pressure persists
TTX-MC138's Phase 2a ctDNA clearance readout in colorectal MRD will determine whether a miRNA-10b inhibitor can become a registrational asset
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
10 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.